Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 1;56(suppl_5):v27-v32.
doi: 10.1093/rheumatology/kex203.

Interstitial lung disease points to consider for clinical trials in systemic sclerosis

Dinesh Khanna  1 , James Seibold  2 , Jonathan Goldin  3 , Donald P Tashkin  4 , Daniel E Furst  5 , Athol Wells  6
Affiliations
Review

Interstitial lung disease points to consider for clinical trials in systemic sclerosis

Dinesh Khanna et al. Rheumatology (Oxford). .

Abstract

Interstitial lung disease causes major morbidity and mortality in patients with systemic sclerosis (SSc-ILD). Large randomized clinical trials in SSc-ILD have provided important information regarding the feasibility, reliability and validity of outcome measures. Forced vital capacity percentage predicted should be considered as a primary outcome measure, with inclusion of appropriate radiological and patient-reported measures. We provide practical recommendations for trial design in SSc-ILD.

Keywords: interstitial lung disease clinical trials; lung disease; scleroderma.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Steen VD, Medsger TA.. Changes in causes of death in systemic sclerosis, 1972–2002. Ann Rheum Dis 2007;66:940–4. - PMC - PubMed
    1. Tashkin DP, Elashoff R, Clements PJ. et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354:2655–66. - PubMed
    1. Seibold JR, Denton CP, Furst DE. et al. Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum 2010;62:2101–8. - PubMed
    1. Hoyles RK, Ellis RW, Wellsbury J. et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma. Arthritis Rheum 2006;54:3962–70. - PubMed
    1. Khanna D, Seibold JR, Wells A. et al. Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. Curr Rheumatol Rev 2010;6:138–44. - PMC - PubMed

Publication types

MeSH terms